Geoglim-G 2 Tablet PR is a combination oral antihyperglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. The prolonged-release formulation ensures a steady release of active ingredients, promoting sustained plasma concentrations and improved patient compliance through once-daily dosing. Geoglim-G 2 Tablet PR is recommended as an adjunct to diet and exercise when monotherapy with either agent is insufficient to achieve target glycemic levels. It is essential to monitor renal function prior to and during therapy due to Metformin’s renal clearance to minimize the risk of lactic acidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, which often subside with continued use. Hypoglycemia is a potential risk, primarily attributable to Glimepiride, necessitating regular blood glucose monitoring. This combination therapy offers a complementary mechanism of action, making it effective in improving glycemic control in patients with type 2 diabetes mellitus.

Dosage & How to Use